�Eisai Corporation of
North America and its partner Helsinn Healthcare SA announced that
the U.S. Food and Drug Administration (FDA) has sanctioned a new oral
formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of
chemotherapy-induced sickness and emesis (CINV). ALOXI Capsules 0.5 mg for
unwritten administration is indicated for the prevention of acute nausea and
vomiting undermentioned initial and repeat courses of pretty emetogenic
chemotherapy. A unmarried 0.5 mg ALOXI Capsule is administered just about
one hour prior to the begin of chemotherapy.
ALOXI (palonosetron hydrochloride) injection 0.25 mg, a
5-hydroxytryptamine-3 (5-HT3) receptor antagonist, has been available in
the United States for intravenous administration since 2003 for the
prevention of acute and delayed nausea and regurgitation associated with initial
and repeat courses of moderately emetogenic chemotherapy, and for the
prevention of acute nausea and vomiting associated with initial and take over
courses of highly emetogenic chemotherapy. A single 0.25 mg intravenous
dose of ALOXI is administered approximately 30 minutes ahead the start of
chemotherapy.
About Chemotherapy-Induced Nausea and Vomiting (CINV)
Research has shown that patients with
